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Abstract
Background Free fatty acids (FFAs) are known for their dual effects on insulin secretion and pancreatic β-cell survival. 
Short-term exposure to FFAs, such as palmitate, increases insulin secretion. On the contrary, long-term exposure to saturated 
FFAs results in decreased insulin secretion, as well as triggering oxidative stress and endoplasmic reticulum (ER) stress, 
culminating in cell death. The effects of FFAs can be mediated either via their intracellular oxidation and consequent effects 
on cellular metabolism or via activation of the membrane receptor GPR40. Both pathways are likely to be activated upon 
both short- and long-term exposure to FFAs. However, the precise role of GPR40 in β-cell physiology, especially upon 
chronic exposure to FFAs, remains unclear.
Methods We used the GPR40 agonist (GW9508) and antagonist (GW1100) to investigate the impact of chronically modu-
lating GPR40 activity on BRIN-BD11 pancreatic β-cells physiology and function.
Results We observed that chronic activation of GPR40 did not lead to increased apoptosis, and both proliferation and 
glucose-induced calcium entry were unchanged compared to control conditions. We also observed no increase in  H2O2 or 
superoxide levels and no increase in the ER stress markers p-eIF2α, CHOP and BIP. As expected, palmitate led to increased 
 H2O2 levels, decreased cell viability and proliferation, as well as decreased metabolism and calcium entry. These changes 
were not counteracted by the co-treatment of palmitate-exposed cells with the GPR40 antagonist GW1100.
Conclusions Chronic activation of GPR40 using GW9508 does not negatively impact upon BRIN-BD11 pancreatic β-cells 
physiology and function. The GPR40 antagonist GW1100 does not protect against the deleterious effects of chronic palmi-
tate exposure. We conclude that GPR40 is probably not involved in mediating the toxicity associated with chronic palmitate 
exposure.
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Introduction
Free fatty acids (FFAs) play a central role in cellular physiol-
ogy as they are both components of biological membranes 
and an important cellular energy source. In pancreatic 
β-cells, FFAs can acutely enhance glucose-stimulated insu-
lin secretion (GSIS) either by modulation of intracellular 
metabolism or via activation of specific G protein-coupled 
receptors (GPCRs) [1–4]. In contrast, chronic exposure of 
pancreatic β-cells to saturated FFAs leads to impaired insu-
lin secretion, β-cell dysfunction and apoptosis, a condition 
that has been termed lipotoxicity [5–12].
Lipotoxicity is a complex condition and several differ-
ent molecular mechanisms have been suggested to underlie 
chronic FFA toxicity in β-cells. These mechanisms include, 
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(i) generation of reactive oxygen species (ROS) from both 
mitochondrial and non-mitochondrial sources, accompanied 
by a reduced expression of antioxidant enzymes [10, 12, 13]; 
(ii) induction of ER stress, particularly the unfolded protein 
response (UPR) [6–9, 14]; and (iii) chronic stimulation of 
the FFA receptor GPR40 (FFAR1), which ultimately leads 
to apoptosis [15–17].
GPR40 (FFAR1) is a GPCR that is activated by both satu-
rated and unsaturated, medium- to long-chain FFAs, includ-
ing palmitate, oleate and linoleate [18–20]. Previously, it 
was reported that GPR40, which is highly expressed in 
pancreatic β-cells, contributes to FFA-induced GSIS [21]. 
Further studies showed that the Gαq-PLC pathway, PDK-1, 
and intracellular calcium are likely involved in this effect 
[4, 20–22] (Fig. 1a). Based in part on these results, GPR40 
emerged as a promising therapeutic target for type 2 diabetes 
mellitus (T2DM), resulting in the development of several 
agonist molecules targeting this receptor [23–26].
Positive effects of GPR40 agonists on insulin secretion 
and viability have been reported in studies employing both 
rodent and human-derived pancreatic islets, as well as in 
β-cell lines (reviewed elsewhere) [27, 28]. Furthermore, the 
GPR40 agonist, TAK-875, reached the stage for human clini-
cal trials, demonstrating improved insulin secretion and little 
risk for hypoglycemic events [25, 29–32]. In contrast, other 
studies have reported that chronic stimulation of GPR40 
may be related to impaired insulin secretion and apoptosis 
[15, 17, 33–35] and the clinical trial using TAK-875 was 
terminated prematurely due to problems with liver toxic-
ity [36]. Therefore, to date, no consensus has been reached 
concerning the impact of chronic GPR40 stimulation on 
β-cell function and fitness. Potential molecular mechanisms 
relating chronic GPR40 stimulation to changes in β-cell 
physiology are, thus, likewise very unclear. Consequently, 
the safety and efficacy of long-term use of GPR40 agonists 
in human patients remain an open question.
In this study, we sought to investigate the impact of 
chronic GPR40 activation on β-cell viability and function 
using the GPR40 agonist GW9508. Specifically, we focused 
on  Ca2+ homeostasis, induction of UPR and changes in intra-
cellular  H2O2 levels. Furthermore, we employed a GPR40 
antagonist (GW1100) to investigate the role of GPR40 in 
the deleterious effects of chronic palmitate exposure. We 
observed that chronic GPR40 stimulation does not lead to 
changes in pancreatic β-cell viability,  Ca2+ homeostasis, 
UPR induction or  H2O2 levels. Furthermore, we observed 
no protective effect of GRP40 inhibition in chronic palmitate 
exposure.
Results
Chronic activation of GPR40 signaling does not lead 
to increased  H2O2 production
Acute GPR40 activation has been shown to lead to increased 
ROS production via NADPH oxidases. However, the impact 
of chronic GPR40 activation on cellular ROS production is 
unclear. We considered it plausible that a long-term stimu-
lation of ROS production may be involved in the reported 
toxicity of chronic GPR40 activation by small molecule 
GPR40 agonists.
Many methods for measuring intracellular ROS are prone 
to artifacts, are not able to monitor dynamic changes in ROS 
levels, offer little insight into subcellular ROS distribution 
and have poor ROS species specificity. We, therefore, sought 
to use the genetically encoded  H2O2 sensor, roGFP2-Orp1, 
targeted to either the mitochondrial matrix or the cytosol/
nucleus to overcome some of these limitations and to gain 
insight into subcellular compartment-specific  H2O2 changes 
following chronic GPR40 activation [37, 38]. Specifically, 
we generated BRIN-BD11 cells stably expressing the mito-
chondrial matrix-targeted  H2O2 sensor, mito-roGFP2-Orp1, 
or the cytosolic/nuclear localized sensor, roGFP2-Orp1. 
First, we demonstrated successful expression of the mito-
chondrial and cytosolic/nuclear sensor in BRIN-BD11 cells 
following excitation at either 405 nm or 488 nm (Fig. 1b). 
Fluorescence microscopy revealed that both sensors respond 
as expected to disulfide reducing (10-mM DTT) and oxidiz-
ing (50-μM  H2O2) conditions, as indicated by ratiometric 
changes in fluorescence emission intensity following excita-
tion at either 405 nm or 488 nm, henceforth referred to as 
the 405/488 nm ratio (Fig. 1b).
Fig. 1  Signaling pathways activated by FFA and GPR40 agonists. 
a FFAs can enter the cells and be translocated to the mitochon-
dria via carnitine palmitoyltransferase 1 (CPT1) to be oxidized by 
β-oxidation. Long- and very-long-chain fatty acids are oxidized in 
peroxisomes, which generates  H2O2. Long-chain saturated or unsat-
urated FFAs can also bind to Gαq-protein-coupled receptor GPR40 
located in the plasma membrane. Acute activation of GPR40 by FFAs 
or agonists as GW9508 activates the phospholipase C (PLC) / dia-
cylglycerol (DAG) pathway, which, respectively, activates PKC and 
mobilizes calcium from the endoplasmic reticulum (ER), potentiat-
ing the insulin release. GPR40 activation also activates PKD1, which 
acts on actin filaments to increase insulin secretion. Both activation of 
PKC and the β-oxidation may lead to the production of reactive oxy-
gen species (ROS) in the cytosol by the NADPH oxidase 2 (NOX2) 
complexes and by the electron transport chain in the mitochondrial 
matrix, respectively. Specific sensors for hydrogen peroxide  (H2O2) 
targeted to the mitochondrial matrix (Mt-roGFP2-Orp1) or in the 
cytosol (roGFP2-Orp1) were used herein to assess the  H2O2 produc-
tion by different compartments. b Fluorescence of BRIN-BD11 cells 
expressing roGFP2-Orp1 in the mitochondrial matrix (Mito) or in the 
cytosol (Cyto) following excitation at 405 nm or 488 nm and the ratio 
(405/488) after addition of 10-mM DTT or 50-µM  H2O2. Numbers 
represent the non-normalized ratio after addition of DTT or 50  µM 
 H2O2. c, d Response of Mt-roGFP2-Orp1 (c) or roGFP2-Orp1 cells 
(d) expressed in BRIN-BD11 exposed to exogenously applied  H2O2 
at the concentrations indicated
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Next, we developed a fluorescence plate reader-based 
assay to enable us to monitor dynamic changes in roGFP2-
Orp1 oxidation and, thus,  H2O2 levels. With this assay, 
we observed a dose-dependent increase in the 405/488 nm 
ratio and, therefore, in roGFP2-Orp1 oxidation in both the 
mitochondrial matrix (Fig. 1c) and the cytosol (Fig. 1d), 
following the exogenous addition of  H2O2. We, there-
fore, conclude that both sensors are capable of reporting 
changes in  H2O2 concentrations in BRIN-BD11 cells.
We next investigated whether chronic treatment of our 
sensor-expressing BRIN-BD11 cells, with the GPR40 ago-
nist GW9508, leads to  H2O2 changes. GW9508 is an ago-
nist of the FFAs receptors GPR40 and GPR120, with 100-
fold selectivity to GPR40 in comparison to GPR120 [19]. 
To assess  H2O2 changes, we incubated BRIN-BD11 cells 
for 48 h with GW9508 and subsequently measured the 
405/488 nm ratio of both mitochondrial matrix (Fig. 2a) 
and cytosol (Fig. 2b) targeted roGFP2-Orp1 sensors. Inter-
estingly, in both compartments, we observed no change 
in roGFP2 oxidation and, therefore, no change in  H2O2 
levels. Furthermore, we incubated cells with the superox-
ide  (O2.−)-reactive small molecule dye, dihydroethidium 
(DHE). Similarly, we also observed no increase in DHE 
fluorescence in GW9508-treated cells (Fig. 2c). In con-
trast, chronic treatment with the GPR40 non-competitive 
antagonist, GW1100, led to significantly increased oxi-
dation of the mitochondrial matrix (Fig. 2a) and cyto-
solic (Fig. 2b) roGFP2-Orp1 sensors, as well an apparent 
increase in DHE fluorescence, although this was not sta-
tistically significant (Fig. 2c).
Fig. 2  ROS production of BRIN-BD11 cells. a, b Fluorescence exci-
tation ratio of Mt-roGFP2-Orp1 (a) or roGFP2-Orp1 (b) expressed 
in BRIN-BD11 cells after 48 h treatment with either: control (Ctrl), 
100  µM Palmitate (PA), 20  μM GPR40 agonist (GW9508), 10  μM 
GPR40 antagonist (GW1100) and PA + GW1100 in culture media 
with 10  mM glucose. Results are expressed as the normalized ratio 
(405/488 nm) against time (mean ± SEM) of 4–6 technical replicates 
from four independent experiments. Two-way ANOVA followed by 
Tukey was used to compare Ctrl, PA, GW1100 and PA + GW1100; 
Student’s t test was used to compare Ctrl and GW9508. In (a) there 
was a significant effect of PA (F1,88 = 31.06, p < 0.0001) and GW1100 
(F1,88 = 47.59, p < 0.0001). In (b) there was a significant effect of PA 
(F1,87 = 279.7, p < 0.0001) and GW1100 (F1,87 = 129, p < 0.0001). p 
values are shown on the graph and indicate the difference versus con-
trol or difference versus PA in brackets. c Superoxide content after 
48  h of incubation was analyzed by flow cytometry of cells treated 
with DHE. Conditions: control (Ctrl), 100-µM palmitate (PA), 20-μM 
GPR40 agonist GW9508 (GW9508), 10-μM GPR40 antagonist 
(GW1100), PA + GW1100 in culture media with 10-mM glucose 
for 48  h. Results are expressed as mean ± SEM for 4–6 independ-
ent experiments. Two-way ANOVA followed by Tukey was used to 
compare Ctrl, PA, GW1100 and PA + GW1100; Student’s t test was 
used to compare Ctrl and GW9508. There was a significant effect 
of PA (F1,12 = 9.672, p = 0.0090) and not GW1100 (F1,12 = 1.335, 
p = 0.2703). p values are shown at the graph and indicate the differ-
ence versus control
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Acute palmitate exposure has been shown to increase 
ROS production both via activation of NADPH oxidases 
and mitochondrial respiration [2, 39–41] as well as by 
GPR40 activation [1–4]. Chronic palmitate exposure also 
leads to increased ROS [42, 43]; however, whether GPR40 
is involved in this context is unclear. We were able to reca-
pitulate the previously reported increased in ROS production 
upon chronic palmitate exposure. Specifically, after 48 h of 
palmitate treatment, we observed an increased oxidation of 
both mitochondrial matrix (Fig. 2a) and cytosolic (Fig. 2b) 
roGFP2-Orp1 sensors, as well as increased DHE fluores-
cence (Fig. 2c), supporting an increase in  O2.− production 
and subsequent dismutation to  H2O2.
Finally, we monitored cells treated with both GW1100 
and palmitate in combination to test for any involvement 
of GPR40 in ROS production upon chronic palmitate treat-
ment. For the mitochondrial matrix roGFP2-Orp1 sensor, 
we observed a similar increase in oxidation as for palmitate 
or GW1100 treatments alone (Fig. 2a). For the cytosolic 
roGFP2-Orp1 sensor, we observed an increase in oxidation 
larger than for that with palmitate or GW1100 treatments 
alone (Fig. 2b). With DHE we also observed a statistically 
significant increase in fluorescence emission compared to 
control (Fig. 2c). In conclusion, our results surprisingly indi-
cate that chronic GPR40 inhibition, and not chronic activa-
tion, leads to increased  O2.−/H2O2 levels. Hence, we suggest 
that GPR40 activation is not involved in chronic palmitate 
exposure-induced  O2.−/H2O2 production.
Chronic GPR40 activation or inhibition has no effect 
on cell viability
We next tested whether chronic GPR40 activation or inhibi-
tion affects cell viability. We, therefore, treated BRIN-BD11 
cells with GW9508 or GW1100 for 48 h and subsequently 
subjected the cells to three different assays to assess viability 
and proliferation. Using a flow cytometric-based assay for 
apoptotic cells (see materials and methods), we observed no 
decrease in the percentage of viable cells and no increase 
in the percentage of apoptotic or necrotic cells with either 
chronic GW9508 or GW1100 treatment (Fig. 3a–c). Like-
wise, immunostaining against Ki67, a marker of cellular pro-
liferation, revealed no impact of GW9508 treatment (Fig. 3d, 
e). However, we did see a decrease in proliferation of cells 
chronically exposed to GW1100 (Fig. 3d, e). Finally, con-
sistent with Ki67 staining data, a 3-[4,5-dimethylthiazole-
2-yl]-2,5-diphenyltetrazolium bromide (MTT)-based assay 
for cellular metabolic activity revealed no impact of chronic 
GW9508 treatment (Fig. 3f), but did show decreased meta-
bolic activity following chronic GW1100 exposure (Fig. 3f).
We tested whether GPR40 has any role in the toxic-
ity of chronic palmitate exposure on β-cell viability. We 
observed a strong and significant decrease in the number 
of viable cells and an increase in the number of apoptotic 
cells following chronic palmitate treatment (Fig. 3a, b), 
with no changes in the number of necrotic cells (Fig. 3c). 
However, co-treatment of cells with GW1100 had no effect 
on palmitate-induced apoptosis (Fig. 3b). Furthermore, we 
observed that both palmitate and GW1100, either alone or 
in combination, led to decreased proliferation (Fig. 3d, e) 
and decreased metabolic activity (Fig. 3f). Therefore, we 
conclude that palmitate-induced β-cell apoptosis is prob-
ably not mediated through GPR40 activation. On the con-
trary, GPR40 inhibition appears to be detrimental to β-cell 
metabolic activity and proliferation, although the negative 
effects of GPR40 inhibition and palmitate treatment do not 
appear to be additive.
GPR40 is not involved in the calcium response 
of BRIN‑BD11 cells to glucose
We were next interested to assess whether chronic GPR40 
stimulation or inhibition affects the ability of BRIN-
BD11 cells to respond to acute glucose addition. Increase 
in intracellular  Ca2+ upon glucose stimulation is directly 
involved in the mobilization and secretion of the insulin 
granules, thereby reflecting β-cell functionality. Therefore, 
we incubated BRIN-BD11 cells for 48 h with GW9508, 
GW1100, palmitate or palmitate in combination with 
GW1100. Subsequently, we used the  Ca2+ dye, Fura-2 
AM, to monitor cytosolic  Ca2+ changes in response to 
acute addition of 20-mM glucose.
We analyzed two parameters: the resting  Ca2+ after cul-
ture in different conditions, which was calculated by aver-
aging  Ca2+ in the first 5 min of measurement before the 
addition of glucose (Fig. 4b), and, the change in the Fura-2 
AM fluorescence excitation ratio following 14 min of 
acute glucose treatment (Fig. 4c). Interestingly, GW1100, 
but not GW9508, led to a decrease in resting  Ca2+ levels. 
Palmitate treatment also led to a statistically significant 
decrease in resting  Ca2+ levels (Fig.  4a, b). However, 
chronic treatment with either GW9508 or GW1100 did 
not affect the ability of cytosolic  Ca2+ to respond to acute 
glucose treatment (Fig. 4a, c). In contrast, chronic treat-
ment with palmitate abolished the cytosolic  Ca2+ response 
to acute glucose treatment (Fig. 4c). Co-treatment of cells 
with GW1100 and palmitate did not rescue the negative 
effects of palmitate on either resting  Ca2+ levels or the 
ability of  Ca2+ to respond to glucose (Fig. 4a–c). In sum-
mary, we conclude that chronic GPR40 activation or inhi-
bition does not affect the ability of BRIN-BD11 cells to 
respond to acute glucose treatment.
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Chronic GPR40 activation or inhibition does not lead 
to ER stress
It is well understood that chronic exposure to palmitate leads 
to ER stress, which induces UPR activation [8]. Finally, 
therefore, we tested whether GPR40 plays a role in mediat-
ing the induction of ER stress. To this end, we monitored by 
western blot the expression of three key UPR-regulated pro-
teins, namely p-eIF2α, BiP and CHOP after 48 h treatment 
of BRIN-BD11 cells with GW9508, GW1100, palmitate or 
palmitate and GW1100 in combination. We observed no 
effect of GW9508 or GW1100 on p-eIF2α or CHOP lev-
els (Fig. 5a–c). In contrast, palmitate tends to increase both 
p-eIF2α and CHOP levels, which was not rescued in cells 
co-treated with GW1100 (Fig. 5a–c). Finally, we observed 
that no treatment had any effect on BiP levels (Fig. 5a, d). 
However, it is well known that BiP responds to chronic 
palmitate treatment at much earlier time-points and that 
BiP levels have been recovered by 48 h [8]. In conclusion, 
chronic GPR40 activation or inhibition does not induce ER 
stress.
Discussion
T2DM is a serious and growing world health problem. 
Therefore, there is a high degree of interest in the develop-
ment of novel drugs aimed at improving pancreatic β-cell 
function and survival, decelerating disease progression and 
enhancing patient well-being.
GPR40 is a highly expressed FFA receptor that has been 
shown to promote insulin secretion in pancreatic β-cells 
in response to both FFAs and glucose [27]. Consequently, 
there has been considerable interest in the development 
of GPR40 agonists as a possible therapeutic agent for 
stimulating pancreatic β-cells and, thus, for treatment of 
T2DM. Several GPR40 agonists have demonstrated posi-
tive effects on glycemic control in rodents and humans [27, 
28]. Nonetheless, some studies have indicated that chronic 
activation of GPR40 may be detrimental for β-cell fitness 
and therefore, on the contrary, GPR40 antagonists may be 
beneficial for T2DM treatment [15–17, 33–35]. Finally, 
there is considerable discussion concerning the role of 
GPR40 in fatty acid-induced β-cell toxicity [17, 44].
In this study, we able to gain further insight into the 
impact of agonist and antagonist-based chronic activation 
and inhibition of GPR40 on BRIN-BD11 pancreatic β-cell 
line function and viability, as well as the role of GPR40 
in mediating the effects of chronic palmitate exposure. 
Principally, we found that agonist-based chronic activa-
tion of GPR40, did not lead to increased cell apoptosis 
nor did it lead to decreased cellular proliferation or loss 
of metabolic activity. Furthermore, it did not affect  Ca2+ 
homeostasis or the response of  Ca2+ to glucose and did 
not lead to increases in cytosolic or mitochondrial  H2O2 
nor to increased superoxide levels. Therefore, our data 
suggest that 48 h activation of GPR40 does not lead to 
cellular toxicity in BRIN-BD11 β-cells. Our results, there-
fore, do not support a negative role of chronic GPR40 acti-
vation on β-cells. In agreement, Wagner and colleagues 
have also shown that cells treated with another synthetic 
GPR40 agonist, TUG-469, did not show any indication of 
increased apoptosis. Furthermore, when incubated with 
PA, the GPR40 agonist TUG-469, protected INS-1E cells 
from apoptosis [45]. Although toxic effects of the GPR40 
agonist TAK-875 on hepatic cells have been reported dur-
ing phase III clinical trials, it is currently unclear if toxic-
ity was confined to hepatic cells or affected other cells as 
well [36].
Interestingly, we show that chronic incubation of BRIN-
BD11 cells with a GPR40 antagonist, GW1100, led to 
decreased cellular proliferation and metabolic activity. Fur-
thermore, 48 h exposure to the antagonist also increased 
cytosolic and mitochondrial matrix  H2O2 levels. Based on 
our data, we hypothesize that decreased cellular metabolism 
Fig. 3  Apoptosis, metabolic activity and proliferation of BRIN-
BD11 cells. Cells were divided into: control condition (Ctrl), 100-
µM palmitate (PA), 20-μM GPR40 agonist (GW9508), 10  μM 
GPR40 antagonist (GW1100), PA + GW1100 and were treated in 
10-mM glucose for 48 h. Percentage of viable (a), apoptotic (b) and 
necrotic (c) BRIN-BD11 cells after treatment in the different condi-
tions. Analysis was performed by flow cytometry using the ViaCount 
reagent. Results are expressed as mean ± SEM for 6–10 independ-
ent experiments. Two-way ANOVA followed by Tukey was used to 
compare Ctrl, PA, GW1100 and PA + GW1100; Student’s t test was 
used to compare Ctrl and GW9508. There was a significant effect 
of PA (F1,31 = 48.2, p < 0.0001) and not GW1100 (F1,31 = 0.2766, 
p = 0.6027). p values are shown at the graph and indicate the differ-
ence versus control or difference versus PA in brackets. d DAPI and 
Ki67 staining of BRIN-BD11 cells after treatment in different condi-
tions. e Density of Ki67 (%). Results are expressed as mean ± SEM 
for four independent experiments. Two-way ANOVA followed by 
Tukey was used to compare Ctrl, PA, GW1100 and PA + GW1100; 
Student’s t test was used to compare Ctrl and GW9508. There was 
a significant effect of PA (F1,12 = 15.64, p = 0.0019) and GW1100 
(F1,12 = 13.75, p = 0.0030). p values are shown at the graph and indi-
cate the difference versus control. Images were quantified at ImageJ 
Fiji Software. f MTT assay of BRIN-BD11 cells after treatment with 
the different conditions as detailed above. Absorbance was measured 
at 570 nm. Results are expressed as mean ± SEM for four independ-
ent experiments. Two-way ANOVA followed by Tukey was used to 
compare Ctrl, PA, GW1100 and PA + GW1100; Student’s t test was 
used to compare Ctrl and GW9508. There was a significant effect 
of GW1100 (F1,11 = 24.92, p = 0.0004) and not PA (F1,11 = 4.555, 
p = 0.0562). p values are shown at the graph and indicate the differ-
ence versus control or difference versus PA in brackets
◂
1732 E. A. Vilas-Boas et al.
1 3
(and consequently NADPH levels, as suggested by MTT 
assay) could underlie the effects of GW1100 treatment on 
 H2O2 production. This is plausible as NADPH is the ultimate 
source of reductive equivalents for many  H2O2-scavenging 
enzymes. Therefore, the lack of NADPH might ultimately be 
responsible for increased  H2O2 levels, as previously shown 
in pancreatic islets cultured with low glucose [46, 47]. These 
data are also in agreement with the toxic effects of another 
GPR40 antagonist TUG-761. When INS-1E cells were incu-
bated with TUG-761, it led to increased apoptosis, which 
was not further augmented with co-incubation of palmitate 
[45].
It has recently been shown, using several different antag-
onists (ANT203, DC260126 or ANT825) as well as by 
GPR40 knockdown, that the GPR40 pathway mediates a 
palmitate-induced increase in mitochondrial respiration in 
Min6 cells and human islets [48]. The mechanism by which 
inhibition of GPR40 impacts upon respiration is not com-
pletely clear, but might involve PKC,  Ca2+ and production 
of signaling second messengers [48]. Here, we have also 
shown decreased metabolism upon GPR40 antagonism as 
well as lower resting  Ca2+ (Figs. 3f, 4b, respectively). Those 
changes could consequently directly impact on proliferation 
rate, as, for example, seen by decreased Ki67 staining in 
GW1100-treated cells (Fig. 3d, e). Finally, treatment with 
a GPR40 antagonist did not ameliorate any of the negative 
effects of chronic palmitate treatment and, therefore, in our 
cells, palmitate-induced toxicity is likely to be independent 
of GPR40 signaling.
In contrast to our results, several recent studies have sug-
gested that antagonism of GPR40 may represent a more 
effective method for T2DM treatment as compared to 
GPR40 agonism [17, 34, 49]. This was supported by findings 
showing that GPR40-null mice were protected against insu-
lin resistance under high-fat diet [15]. In addition, two differ-
ent GPR40 inhibitors were shown to rescue the deleterious 
Fig. 4  Dynamic measurements of  Ca2+ in BRIN-BD11 cells. Cells 
were divided into: control condition (Ctrl), 100-µM palmitate 
(PA), 20-μM GPR40 agonist(GW9508), 10-μM GPR40 antagonist 
(GW1100) and PA + GW1100, treated in 10-mM glucose for 48  h. 
After the incubation,  Ca2+ measurements were performed using 
Fura-2 AM dye using an Axio Observer seven microscope. Cells 
were first incubated for 5  min without glucose followed by up to 
20 min with 20 mM of glucose. a Calcium dynamics. Glucose con-
centration is indicated above. Two-way ANOVA followed by Tukey 
was used to compare Ctrl, PA, GW1100 and PA + GW1100; Stu-
dent’s t test was used to compare Ctrl and GW9508. b Resting  Ca2+ 
was calculated as an average of the first 5 min of measurement before 
glucose addition. There was no significant effect of PA (F1,90 = 3.423, 
p = 0.0676) or GW1100 (F1,90 = 2.399, p = 0.1250). c Delta was calcu-
lated by averaging data at 18 min minus the average of data at 4 min. 
There was a significant effect of PA (F1,87 = 24.89, p < 0.0001) and 
not GW1100 (F1,87 = 0.0001879, p = 0.9891). Results are expressed as 
mean ± SEM for three independent experiments. p values are shown 
on the graph and indicate the difference versus control
▸
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effects of FFAs on insulin secretion and cell viability [17, 
34]. In one study, Wu et al., also reported a small beneficial 
effect of GPR40 inhibition on palmitate-induced ER stress, 
contrary to our observations. It is currently unclear what 
underlies the opposing results of our study in comparison to 
those of others. However, differences in cell lines, palmitate 
concentration and the specific GPR40 antagonist molecule 
used might all play a role. Furthermore, the possibility for 
off-target effects of any small molecule antagonist cannot 
ever be fully excluded [17]. Furthermore, GPR40 antago-
nists have not been observed to promote better glucose levels 
or improvement in glucose tolerance in animal models [16, 
Fig. 5  Expression of ER stress markers in BRIN-BD11 cells. Cells 
were divided into: control condition (Ctrl), 100-µM palmitate (PA), 
20-μM GPR40 agonist GW9508 (GW9508), 10 μM GPR40 antago-
nist (GW1100), PA + GW1100 and were treated in media contain-
ing 10-mM glucose for 48  h. Western blot analysis was performed 
for the proteins of interest: p-eIF2α, CHOP and BiP, using α-tubulin 
as internal control. a Representative bands and respective α-tubulin. 
Densitometric analysis of western blot: p-eIF2α (b), CHOP (c) and 
BiP (d). Results are expressed as mean ± SEM of 3–5 independ-
ent experiments. Two-way ANOVA followed by Tukey was used to 
compare Ctrl, PA, GW1100 and PA + GW1100; Student’s t test was 
used to compare Ctrl and GW9508. b There was a significant effect 
of PA (F1,12 = 14.41, p = 0.0025) and not GW1100 (F1,12 = 2.691, 
p = 0.1269). c There was a significant effect of PA (F1,8 = 24.68, 
p = 0.0011) and GW1100 (F1,8 = 15.35, p = 0.0044). d There was 
no significant effect of PA (F1,15 = 0.04331, p = 0.8379) or GW1100 
(F1,15 = 0.004461, p = 0.9476). p values are shown on the graph and 
indicate the difference versus control or difference versus PA in 
brackets
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49], which, therefore, suggest they offer little advantage as 
an antidiabetic drug.
In summary, we provide evidence that chronic activa-
tion of GPR40 does not lead to decreased cell viability 
and function or to increased oxidative and ER stresses. 
Nonetheless, our data do support an important role for 
GPR40 signaling in β-cell physiology, as demonstrated by 
the deleterious effects of the antagonist GW1100. Our data 
support the targeting of GPR40 for the treatment of T2DM 
and we believe that more efforts to test different agonists 
in clinical trials should be taken.
Materials and methods
Reagents
Culture medium with or without phenol red (RPMI 
1640), dihydroethidium (DHE), RIPA lysis buffer, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) and Fura-2 AM were obtained from Thermo 
Fischer Scientific (Waltham, MA, USA); palmitic acid 
was obtained from Sigma-Aldrich (St. Louis, MO, USA); 
GW9508 and GW1100 were obtained from Calbiochem/
Merck Millipore (Billerica, MA, USA); ViaCount Rea-
gent was obtained from Merck Millipore (Billerica, MA, 
USA); anti-p-eIF2-α (#9721S), anti-CHOP-10 (#2895S), 
anti-BiP (#3183), anti-α-tubulin (#3873) and anti-Ki67 
(#12202) antibodies were obtained from Cell Signaling 
Technology (Danvers, MA, USA); Alexa Fluor555-conju-
gated anti-rabbit antibody (#A21429) was obtained from 
Invitrogen (Carlsbad, CA, USA).
Stable expression of mito‑ or cyto‑roGFP2‑Orp1 
in BRIN‑BD11 cells
We have recently generated genetically encoded fluores-
cent protein redox sensors, which allow real-time meas-
urements of defined redox species in intact living cells 
and animal models [50]. We are employing these cell lines 
in the context of a newly developed fluorescence plate-
reader-based methodology that allows high-throughput 
screening of multiple different conditions. Herein, BRIN-
BD11 cells expressing the genetically encoded  H2O2 
sensor roGFP2-Orp1 either in the mitochondrial matrix 
(Mito-roGFP2-Orp1 BRIN-BD11) or untargeted in the 
cytosol (roGFP2-Orp1 BRIN-BD11) were generated by 
lentivirus transduction. Briefly, HEK-293FT cells were 
transfected with pLPCX/mito-roGFP2-Orp1 or pLPCX/
roGFP2-Orp1 (encoding the roGFP2-Orp1 probe with 
an N-terminal mitochondrial or non-targeted sequence) 
by calcium phosphate method. After 6 h of transfection, 
cells were washed twice with DMEM medium without 
supplements and transferred to fresh medium. After 48 h 
of transfection, supernatant was collected and passed 
through an Amicon column Spin-X 431,491 (Corning 
Inc., NY, USA). BRIN-BD11 cells (seeded at 3 × 105 cells 
per well in a 6-well plate overnight before experiment) 
were incubated with the virus-containing supernatant in 
RPMI medium (0.1% P/S, 8 µg/ml Polybrene and without 
FCS) overnight at 37 °C in a 5%  CO2 atmosphere. Cells 
were then selected in a medium containing puromycin 
(1 µg/ml) for 2 weeks.
Culture and treatment of cell lines
BRIN-BD11 cells were grown in RPMI 1640 medium with 
10% FCS, 0.1% P/S (100 U/ml penicillin, 0.1 mg/ml strepto-
mycin) and 11.1 mmol/l D-glucose, pH 7.4, in a humidified 
atmosphere of 5%  CO2/95% air at 37 °C. For flow cytom-
etry assays (superoxide measurement and viability) and for 
western blot, cells were seeded at 6 × 104 cells per well in 
500-µl medium in 24-well plates; for the MTT assay and 
assessment of  H2O2, cells were seeded at 7 × 103 cells per 
well in 200-µl medium in 96-well plates; for the evalua-
tion of proliferation by anti-Ki67 staining, cells were seeded 
at 2.5 × 103 cells per condition in 500-µl medium in glass 
coverslips placed in 24-well plates; for the measurement of 
 Ca2+ levels, cells were seeded at 1 × 104 cells per condition 
in 1.5-ml medium in glass coverslips placed in 25  cm2 petri 
dishes. Mito-roGFP2-Orp1 BRIN-BD11 and roGFP2-Orp1 
BRIN-BD11 cells were used for the assessment of  H2O2 
production. For the assessment of  H2O2 and  Ca2+, experi-
ments were performed in complete RPMI medium without 
phenol red to decrease background fluorescence. Cells were 
allowed to adhere overnight and then incubated for 48 h in 
different conditions: 100 µM of PA, 20 µM of the GPR40 
agonist GW9508, 10 µM of the GPR40 antagonist GW1100 
or 100 µM of PA + 10 µM GW1100. All treatments were 
48 h. PA was diluted in 100% ethanol to prepare a stock 
solution with a concentration of 50 mM. For complete solu-
bilization, the stock solutions were mixed thoroughly. Stock 
solutions were prepared fresh for each experiment. GW1100 
and GW9508 were diluted in DMSO to prepare stock solu-
tions of 10 mM and 20 mM, respectively.
Superoxide measurement
After 48 h exposure to treatment, cells were incubated with 
40 µM of DHE dye for 20 min at room temperature. Cells 
were then washed with PBS and incubated with 100 µl of 
trypsin for 5 min at 37 °C. Trypsin was inactivated with 
200 µl of complete RPMI medium and cells were transferred 
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to a 96-well plate. Fluorescence was assessed by the flow 
cytometer Guava EasyCyte (Millipore). Values of each 
experiment were normalized by the respective control val-
ues (considered as 1).
Hydrogen peroxide  (H2O2) measurement
Measurements of intracellular levels of  H2O2 were per-
formed in mito-roGFP2-Orp1 BRIN-BD11 and roGFP2-
Orp1 BRIN-BD11 cells after 48 h exposure to the different 
conditions, using the CLARIOstar Microplate Reader (BMG 
LABTECH, Ortenberg, Germany). Temperature was set to 
37 °C and atmospheric conditions were set to 5%  CO2 with 
the ventilation left open for  O2 to diffuse freely in the system 
(18.8%  O2). Cytosolic and mitochondrial roGFP emission 
was detected after excitation at 405 and 488 nm and emis-
sion at 500–530 nm. The ratio 405/488 nm was calculated 
and plotted against time using GraphPad Prism.
Viability
Cell viability after 48 h of treatment was assessed by ViaCo-
unt Reagent, which distinguishes between viable and non-
viable cells (divided into apoptotic and necrotic/dead cells). 
Protocol was performed as previously described [51] and 
fluorescence was assessed by the flow cytometer Guava 
EasyCyte (Millipore).
Proliferation
The proliferation of the cells after 48 h of treatment was 
determined after immunostaining with anti-Ki67. After 
48 h of incubation, the cells were fixed for 30 min in 4% 
paraformaldehyde (in PBS) and permeabilized for 10 min 
in PBS containing 0.2% Triton X-100 and 2% bovine serum 
albumin (BSA) at room temperature. Unspecific binding 
sites were blocked by incubation with 1% BSA in PBS for 
15 min before cells were incubated overnight at 4 °C with 
the specific anti-Ki67 primary antibody. After washing with 
PBS, cells were incubated with secondary Alexa Fluor555-
conjugated anti-rabbit antibody for 1 h at room tempera-
ture. Subsequently, the cells were washed and incubated for 
15 min at 37 °C with 3.7% bisBenzimide solution to stain the 
nuclei and finally sealed with mounting media. Images were 
captured by fluorescence microscopy (BX60F; OlympusOp-
tical, Tokyo, Japan) and quantified at ImageJ Fiji Software.
MTT assay
The metabolic activity of cells after 48 h of treatment was 
determined using the MTT assay, as described by the manu-
facturer. Briefly, after addition of the MTT reagent to the 
samples, the purple formazan crystals formed were dissolved 
in DMSO and the absorbance was read at 570 nm on the 
microplate reader Synergy H1 (Biotek, Vermont, USA).
Ca2+ measurements
For the analysis of cytosolic calcium after 48 h of treatment, 
BRIN-BD11 cells were loaded with 2-µM Fura-2 AM for 
25 min in a bicarbonate-buffered Krebs solution and placed 
under the microscope Axio Observer 7 (Zeiss, Oberkochen, 
Germany). Measurements were made every 2 s for 15 min 
during two steps: first in buffer without glucose, followed by 
addition of high glucose (20 mM). Cells were imaged using 
excitation 340/380 nm and emission 505 nm.
Western blot
Protein expression of ER stress markers was assessed by west-
ern blot. Total protein extracts were separated by SDS-PAGE 
and transferred to nitrocellulose membranes. Membranes were 
probed with specific antibodies against p-eIF2-α, CHOP and 
BiP. Anti-α-tubulin was used as internal control.
Statistical analyses
Results are presented as mean ± SEM from at least three inde-
pendent experiments. Statistical analysis was carried out at the 
GraphPad Prism seven software. Two-way ANOVA followed 
by Tukey was used to compare differences between the fol-
lowing groups: control, PA, GW1100 and PA + GW1100; Stu-
dent’s t test was used to compare differences between control 
and GW9508. In the supplementary Fig. 2 , one-way ANOVA 
followed by Dunnet was used. Confidence levels were set to 
p < 0.05. P values, F values and degree of freedom for the two-
way ANOVA (column factor and row factor) are presented in 
the figure legends. P values for the Tukey post test or Student’s 
t-test are presented in the figures.
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